[Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults]

Danish Centre for Evaluation and Health Technology Assessment
Record ID 32005000560
Authors' recommendations: Several scientific studies have documented that treatment with omalizumab results in fewer and milder asthma exacerbations per person, and that fewer patients suffer asthma exacerbations. In addition, hospitalization time shortens and quality of life improves. Few side effects have been observed, although a few of these may be serious. Omalizumab treatment will probably cost approx. USD 10–12,000 per year. Even when used solely in cases of severe asthma, it is unclear whether omalizumab can reduce the costs associated with hospitalization, emergency room visits and loss of production sufficiently to render the treatment cost effective.
Project Status: Completed
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Denmark
MeSH Terms
  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal
  • Asthma
  • Hypersensitivity
  • Immunoglobulin E
Organisation Name: Danish Centre for Evaluation and Health Technology Assessment
Contact Address: National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67
Contact Name: dacehta@sst.dk
Contact Email: dacehta@sst.dk
Copyright: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.